IGI Laboratories (IG) 9.07 $IG IGI Laboratories To

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:39 PM

IGI Laboratories (IG) 9.07 $IG

IGI Laboratories To Present At 14th Annual Needham Healthcare Conference On April 14, 2015
PR Newswire - Mon Apr 13, 3:05PM CDT
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based specialty generic pharmaceutical company, will be presenting tomorrow at the 14th Annual Needham Healthcare Conference. The Conference will take place on April 14-15, 2015, at The Westin Grand Central Hotel in New York, NY.
IG: 9.07 (+0.35)

IGI Laboratories, Inc. Announces First ANDA Submission Of 2015
PR Newswire - Thu Mar 26, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-three.
IG: 9.07 (+0.35)

IGI Laboratories, Inc. Appoints John Celentano to Board of Directors
PR Newswire - Mon Mar 23, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced that it has appointed John Celentano to its Board of Directors. Mr. Celentano will also serve on the Company's Audit Committee.
IG: 9.07 (+0.35)

Why IGI, Laboratories (IG) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 7:36AM CDT
IGI, Laboratories (IG) has witnessed a significant price decline in the past four weeks, and it has lately seen significant negative earnings estimate revisions as well.
LCI: 66.45 (-0.28), IG: 9.07 (+0.35)

IGI Laboratories (IG) Downgraded From Buy to Hold
at The Street - Tue Mar 10, 11:00AM CDT
IGI Laboratories (IG) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
IG: 9.07 (+0.35)

Technical Snapshot on Pharma Stocks -- Pfizer, Zogenix, Sanofi, Nektar Therapeutics, and IGI Laboratories
PR Newswire - Tue Mar 10, 9:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ZGNX: 1.63 (-0.02), PFE: 34.93 (+0.04), SNY: 51.59 (+0.03), IG: 9.07 (+0.35), NKTR: 10.90 (+0.16)

Insider Trading Alert - HYGS, STLY And IG Traded By Insiders
at The Street - Mon Mar 09, 1:00PM CDT
Stocks with insider trader activity include HYGS, STLY and IG
HYGS: 12.07 (+0.18), STLY: 3.08 (+0.01), IG: 9.07 (+0.35)

IGI Laboratories To Present At 27th Annual ROTH Capital Conference On March 9, 2015
PR Newswire - Mon Mar 09, 9:30AM CDT
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based specialty generic pharmaceutical company, will be presenting today at the 27th Annual ROTH Conference. The Conference will take place on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel, Dana Point, California.
IG: 9.07 (+0.35)

InsiderInsights.com Daily Round Up 3/6/15: BK, OAS, GPC, CAPL
InsiderInsights - at Seeking Alpha - Sat Mar 07, 11:01AM CST

OCR: 84.52 (+3.45), GPC: 93.02 (+0.57), BRCM: 46.18 (+2.20), QTWO: 20.06 (+0.04), CB: 99.30 (-0.44), AMRI: 18.48 (-0.19), LKFN: 40.28 (-0.05), PCLN: 1,212.90 (+18.64), HTWO: 9.70 (-0.11), GGP: 28.67 (-0.03), ARMK: 31.30 (+0.32), CAPL: 32.83 (+0.15), ETFC: 28.60 (+1.07), TWTR: 51.73 (+0.41), BLMN: 22.70 (unch), GRPN: 7.07 (-0.06), BK: 42.43 (+1.39), IG: 9.07 (+0.35), OAS: 16.47 (-0.36), ALCO: 48.09 (-1.52)

IGI, Laboratories (IG) Falls: Stock Goes Down 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 7:47AM CST
IGI, Laboratories saw a big move last session, as the company’s shares fell by nearly 12% which continued the downtrend for the company
LCI: 66.45 (-0.28), IG: 9.07 (+0.35)

IGI Laboratories' (IG) CEO Jason Grenfell Gardner on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 9:02PM CST

IG: 9.07 (+0.35)

IGI Laboratories EPS of $0.09
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:09PM CST

IG: 9.07 (+0.35)

IGI Laboratories Announces Fourth Quarter And Year End 2014 Results
PR Newswire - Mon Mar 02, 3:01PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2014.
IG: 9.07 (+0.35)

5 Stocks With Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Sat Feb 28, 8:04AM CST
With the U.S. stock market hitting record highs of late and red hot sectors like health care sporting some jaw-dropping premiums, it's getting harder and harder to find stocks with compelling valuations. That being said, there are still a handful of...
VRX: 206.93 (-3.92), FLML: 15.84 (-0.33), PTX: 7.44 (-0.05), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15), GSK: 46.57 (-0.67), EGRX: 60.53 (+1.22), SNY: 51.59 (+0.03), ARDX: 12.51 (-0.01), IG: 9.07 (+0.35)

PTC Therapeutics (PTCT) Jumps: Stock Moves 9.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 8:11AM CST
PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise roughly 10% on the day.
PTCT: 70.98 (unch), IG: 9.07 (+0.35)

Egalet (EGLT) Falls: Stock Goes Down 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:39AM CST
Shares of Egalet (EGLT) fell by nearly 8% on the day. This reverses the recent trend for EGLT as the stock is now up over 60% in the past one-month time frame. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
EGLT: 10.34 (-0.27), IG: 9.07 (+0.35)

Forget MannKind Corporation; Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Sun Feb 22, 12:01PM CST
Fits and starts in developing a revolutionary new inhaled insulin have meant that Al Mann's MannKind has had more than its fair share of pops and drops over the past few years. MannKind won FDA approval for Afrezza last summer and announced its...
VRX: 206.93 (-3.92), INSY: 62.10 (+0.76), AZN: 73.35 (+0.65), ACOR: 33.34 (-1.33), SNY: 51.59 (+0.03), MNKD: 4.90 (-0.09), IG: 9.07 (+0.35)

Concert Pharmaceuticals (CNCE) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 20, 7:51AM CST
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
IG: 9.07 (+0.35), CNCE: 14.83 (+0.26)

What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories
PR Newswire - Thu Feb 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
VICL: 1.01 (-0.02), HEB: 0.25 (+0.01), AST: 13.61 (-0.11), IG: 9.07 (+0.35)

Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 7:51AM CST
Ariad Pharmaceuticals Inc. (ARIA) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ARIA: 9.23 (-0.04), IG: 9.07 (+0.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honoring Boston's Architects Changing the Game

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

SOCSA: The Future of Safety in Confined Spaces?

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Retirement Dreams Dashed: 61% Withdraw Early

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

NVIDIA Faces Legal Turbulence: CEO's Exit Sparks Chaos

Jensen Huang's Sudden Exit: A Barrage of Headlines In what feels like a blow delivered by a sledgehammer, NVIDIA is rocked by the abrupt resignation of its iconic co-founder and CEO, Jensen Huang. This isn't some quiet departure into the night. Nope, it's more like a cannonball being fired into the investor lounge, leaving a wreckage for all to navigate through. Huang's...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Sino Bio Speeds AI Drug Discovery with 4RISE Launch

AI Meets Real-World Validation In the world of cutting-edge biotech, Sino Biological is turning heads with its latest move. If you're in the game of AI-driven drug discovery, their new 4RISE™ high-throughput wet-lab validation services could be the breakthrough you've been waiting for. Why? Well, the promise of AI is dazzling, but it all boils down to how fast you can...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Fluence Energy Faces Class Action: Investor Insights

Investor Blues: Fluence Under the Weather If you've been keeping an eye on Fluence Energy (NASDAQ:FLNC), you're probably clutching your metaphorical pearls right now. Here's the scoop: on November 2, 2026, the stock took another nosedive—dropping nearly 9%—as the company announced that both CEO Julian Nebreda and CFO Ahmad Pasha had packed their bags. A leadership...

Missoula Inventor Offers Handy Phone Solution on the Move

Adjustable Convenience for the Modern Commuter When you're commuting or just lounging around, less hand strain and more comfort sounds like a no-brainer, right? Well, an inventive soul from Missoula, Montana, just might have cracked this little nut with a gizmo they're calling the COMMUTER PHONE. Imagine never having to juggle your phone during those bumpy moments on the...

PangeAI and Sky Blue Transform Data Center Decisions

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...